Delivering the bullet to the right intracellular target: A cellular perspective on drug delivery

Targeted Delivery of Small and Macromolecular Drugs

Volumn , Issue , 2010, Pages 219-254

  Tarragó Trani, Maria Teresa ^a   Storrie, Brian ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952910422     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420087734     Document Type: Chapter

References (208)

1. Behnia R, Munro S. Organelle identity and the signposts for membrane traffic. Nature 2005; 438: 597-604.
2. De Matteis MA, Luini A. Exiting the Golgi complex. Nat Rev Mol Biol 2008; 7: 273-284.
3. Grosshans BL, Ortiz D, Novick P. Rabs and their effectors: Achieving specificity in membrane traffic. Proc Natl Acad Sci USA 2006; 103: 11821-11827.
4. Lowenthal, MS, Howell, KE, Wu, CC. Proteomic analysis of the stacked Golgi complex. Methods Mol Biol 2008; 432: 37-49.
5. Mayor S, Pagano R. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 8: 603-612.
6. Mellman I, Warren G. The road taken: Past and future foundations of membrane traffic. Cell 2000; 100: 99-112.
7. Seaman MN. Endosome protein sorting: Motifs and machinery. Cell Mol Life Sci 2008; 65: 2842-2858.
8. Storrie B. Maintenance of Golgi apparatus structure in the face of continuous protein recycling to the endoplasmic reticulum: Making ends meet. Int Rev Cytol 2005; 244: 69-94.
9. van Vliet C, Thomas EC, Merino-Trigo A, Teasdale RD, Gleeson PA. Intracellular sorting and transport of proteins. Prog Biophys Mol Biol 2003; 83: 1-45.
10. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
11. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci 2007; 8: 499-509.
12. Small SA, Gandy S. Sorting through the cell biology of Alzheimer’s disease: Intracellular pathways to pathogenesis. Neuron 2006; 52: 15-31.
13. Zhang YW, Xu H. Molecular and cellular mechanisms for Alzheimer’s disease: Understanding APP metabolism. Curr Mol Med 2007; 7: 687-698.
14. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing and function. J Biol Chem 2008; 283: 29615-29619.
15. Vetrivel K, Thinakaran G. Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments. Neurology 2006; 66(Suppl 1): S69-S73.
16. Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the β-secretase, in Alzheimer disease pathophysiology. J Biol Chem 2008; 283: 29621-29625.
17. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheirmer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735-741.
18. Steiner H, Fluhrer R, Haass C. Intramembrane proteolysis by γ-secretase. J Biol Chem 2008; 283: 29627-29631.
19. Lah JJ, Levey AI. Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments. Mol Cell Neurosci 2000; 16: 111-126.
20. Carey RM, Balcz BA, Lopez-Coviella I, Slack BE. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol 2005; 6: 30.
21. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer’s disease β-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006; 103: 11172-11177.
22. Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 2003; 116(Pt 16):3339-3346.
23. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron 2003; 37: 925-937.
24. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 2003; 72: 395-447.
25. Small SA. Retromer sorting: A pathogenic pathway in late-onset Alzheimer’s disease. Arch Neurol 2008; 65: 323-328.
26. Bonifacino JS, Hurley JH. Retromer. Curr Op Cell Biol 2008; 20: 427-436.
27. Seaman MN. Recycle your receptors with retromer. Trends Cell Biol 2005; 15: 68-75.
28. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apoliprotein E receptor LR11 in Alzheimer’s disease. Arch Neurol 2004; 61: 1200-1205.
29. Small SA, Kent K, Pierce A, Leung C, Kang MS, Okada H, Honig L, Vonsattel JP, Kim TW. Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann Neurol 2005; 58: 909-919.
30. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer’s disease. Nat Genet 2007; 39: 168-177.
31. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CAF, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow T. Neuronal sorting protein-related receptor sorLA LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA 2005; 102: 13461-13466.
32. Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes A, Petersen CM. Sorting by the cytoplasmic domain of the amyloid precursor protein binding receptor SorLA. Mol Cell Biol 2007; 27: 6842-6851.
33. Offe K, Dodoson SE, Shoemaker T, Fritz JJ, Gearing M, Levey A, Lah J. The lipoprotein receptor LR11 regulates amyloid production and amyloid precursor traffic in endosomal compartments. J Neurosci 2006; 26: 1596-1603.
34. Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow T. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem 2007; 282: 32956-32964.
35. Spolgen R, von Arnim CAF, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and β-secretase β-site APP-cleaving enzyme. J Neurosci 2006; 26: 418-428.
36. Mari M, Bujny MV, Zeuschner D, Geerts WJC, Griffith J, Petersen CM, Cullen PJ, Klumperman J, Geuze HJ. SNX1 defines an early endosomal recycling exit for sortilin and mannose-6-phosphate receptors. Traffic 2008; 9: 380-393.
37. Babuke T, Tikkanen R. Dissecting the molecular function of reggie/flotillin proteins. Eur J Cell Biol 2007; 86: 525-532.
38. Langhorst MF, Reuter A, Stuermer CAO. Scaffolding microdomains and beyond: The function of reggie/flotillin proteins. Cell Mol Life Sci 2005; 62: 2228-2240.
39. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem 2009; 78: 857-902.
40. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol 2006; 8: 46-54.
41. Laude AJ, Prior IA. Plasma membrane microdomains: Organization, function and trafficking. Mol Memb Biol 2004; 21: 193-205.
42. Langui D, Girardot N, Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C. Subcellular topography of neuronal Aβ peptide in APPxPS1 transgenic mice. Am J Pathol 2004; 165: 1465-1477.
43. Kokubo H, Lemere CA, Yamaguchi H. Localization of flotillins in human brain and their accumulation with the progression of Alzheimer’s disease pathology. Neurosci Lett 2000; 290: 93-96.
44. Schneider A, Rajendran L, Honsho M, Gralle N, Donnert G, Wouters F, Hell SW, Simons M. Flotillindependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 2008; 28: 2874-2882.
45. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 2006; 23: 111-122.
46. Garcia-Marcos M, Pochet S, Tandel S, Fontanils U, Astigarraga E, Fernandez-Gonzalez JA, Kumps A, Marino A, Dehaye JP. Characterization and comparison of raft-like membranes isolated by two different methods from rat submandibular gland cells. Biochim Biophys Acta 2006; 1758: 796-806.
47. Pike LJ. Lipid rafts: Bringing order to chaos. J Lipid Res 2003; 44: 655-667.
48. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
49. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci USA 2003; 100: 5813-5818.
50. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
51. Benjannet S, Elagoz A, Wickham L, Mamarbachi M, Munzer JS, Basak A, Lazure C, Cromlish JA, Sisodia S, Checler F, Chrétien M, Seidah NG. Post-translational processing of β-secretase (β-amyloidconverting enzyme) and its ectodomain shedding: The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J Biol Chem 2001; 276: 10879-10877.
52. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113-123.
53. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 2005; 280: 36818-36823.
54. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006; 66: S79-S85.
55. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861.
56. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
57. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
58. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks, LM, Liebsack C. Reduced risk of incident AD in elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008; 5: 416-421.
59. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer’s disease. Arch Neurol 2008; 65: 1031-1038.
60. Roberson ED, Mucke L. 100 years and counting: Prospects for defeating Alzheimer’s disease. Science 2006; 314: 781-784.
61. Evin G. γ-Secretase modulators: Hopes and setbacks for the future of Alzheimer’s treatment. Expert Rev Neurother 2008; 8: 1611-1613.
62. Weggen S, Rogers M, Eriksen J. NSAIDs: Small molecules for prevention of Alzheimer’s disease or precursors for future drug development. Trends Pharmacol Sci 2007; 28: 536-543.
63. Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer’s disease. Neurotherapeutics 2008; 5: 391-398.
64. Ghosh AK, Gemma S, Tang J. β-Secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics 2008; 5: 399-408.
65. Hills ID, Vacca JP. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Dev 2007; 10: 383-391.
66. Silvestri R. Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease. Med Res Rev 2009; 2: 295-338.
67. Tung JS, Davis DL, Anderson JP, Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V. Design of substrate-based inhibitors of human β-secretase. J Med Chem 2002; 45: 259-262.
68. Wolfe MS. Selective amyloid-β lowering agents. BMC Neurosci 2008; 9(Suppl 2): S4.
69. Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Knolker HJ, Simons K. Efficient inhibition of the Alzheimer’s disease β-secretase by membrane targeting. Science 2008; 320: 520-523.
70. Johannes L, Popoff V. Tracing the retrograde route in protein trafficking. Cell 2008; 135: 1175-1187.
71. Tarragó-Trani MT, Storrie B. Alternate routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum. Adv Drug Deliv Rev 2007; 59: 782-797.
72. Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J 2004; 377: 1-16.
73. Rodemer C, Haucke V. Clathrin/AP-2-dependent endocytosis: A novel playground for the pharmacological toolbox. Handb Exp Pharmacol 2008; 186: 105-122.
74. Sandvig K, Torgersen ML, Raa HA, van Deurs B. Clathrin-independent endocytosis: From nonexisting to an extreme degree of complexity. Histochem Cell Biol 2008; 129: 267-276.
75. Ohno H, Stewart J, Fournier MC, Bosshart H, Rhee I, Miyatake S, Saito T, Gallusser A, Kirchhausen T, Bonifacino JS. Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 1995; 269: 1872-1875.
76. Simonsen A, Bremnes B, Nordeng TW, Bakke O. The leucine-based motif DDQxxLI is recognized both for internalization and basolateral sorting of invariant chain in MDCK cells. Eur J Cell Biol 1998; 76: 25-32.
77. Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, Hopkins CR, Evans PR, MacMahon HT. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001; 291: 1051-1055.
78. Takei K, Haucke V. Clathrin-mediated endocytosis: Membrane factors pull the trigger. Trends Cell Biol 2001; 11: 385-391.
79. Jin AJ, Nossal R. Topological mechanisms involved in the formation of clathrin-coated vesicles. Biophys J 1993; 65: 1523-1537.
80. Schmidt AA. Membrane transport: The making of a vesicle. Nature 2002; 419: 347-349.
81. Kozlov MM. Fission of biological membranes: Interplay between dynamin and lipids. Traffic 2001; 2: 51-65.
82. Lee E, De Camilli P. Dynamin at actin tails. Proc Natl Acad Sci USA 2002; 96: 161-166.
83. Merrifield CJ, Feldman ME, Wan L, Almers W. Imaging actin and dynamin recruitment during invagination of single clathrin-coated pits. Nat Cell Biol 2002; 4: 691-698.
84. Rodal SK, Skeretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell 1999; 10: 961-974.
85. Subtil A, Gaidarov I, Kobylarz, K, Lampson MA, Keen JH, McGraw TE. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA 1999; 96: 6775-6780.
86. Palade GE. Fine structure of blood capillaries. J Appl Phys 1953; 24: 1424.
87. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1955; 1: 445-458.
88. Couet J, Belanger MM, Roussel E, Drolet MC. Cell biology of caveolae and caveolin. Adv Drug Del Rev 2001; 49: 223-235.
89. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 1997; 9: 534-542.
90. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8: 185-194.
91. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Genney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 1992; 68: 673-678.
92. Sharma DK, Brown JC, Choudhury A, Peterson TE, Holicky E, Marks DL, Simari R, Parton RG, Pagano RE. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell 2004; 15: 3114-3122.
93. Shajahan AN, Timblin BK, Sandoval R, Tiruppathi C, Malik AB, Minshall RD. Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J Biol Chem 2004; 279: 20392-20400.
94. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci 2003; 116: 4707-4714.
95. Nichols BJ, Lippincott-Schwartz J. Endocytosis without the clathrin coats. Trends Cell Biol 2001; 13: 406-412.
96. Schlegel A, Lisanti MP. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interaction in vivo. J Biol Chem 2000; 275: 21605-21617.
97. Parton RG, Hanzal-Bayer M, Hancock JF. Biogenesis of caveolae: A structural model for caveolininduced domain formation. J Cell Sci 2006; 119: 787-796.
98. Thomsen P, Roepstorff K, Stahlhut M, van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 2002; 13: 238-250.
99. Fujimoto T, Miyawaki A, Mikoshiba K. Inositol 1,4,5-trisphosphate receptor-like protein in plasmalemmal caveolae is linked to actin filaments. J Cell Sci 1995; 108: 7-15.
100. Stahlhut M, van Deurs B. Identification of filamin as a novel ligand for caveolin-1: Evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol Biol Cell 2000; 11: 325-337.
101. Parton RG, Joggerst B, Simons K. Regulated internalization of caveolae. J Cell Biol 1994; 127: 1199-1215.
102. Le PU, Guay G, Altschuler Y, Nabi IR. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J Biol Chem 2002; 277: 3371-3379.
103. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular transport pathway to the ER. Nat Cell Biol 2001; 3: 473-483.
104. Pelkmans L, Puntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40- induced internalization of caveolae. Science 2002; 296: 535-539.
105. Torgersen ML, Skretting G, van Deurs B, Sandvig K. Internalization of Cholera toxin by different endocytic mechanisms. J Cell Sci 2001; 114: 3737-3747.
106. Damm EM, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, Helenius A. Clathrin- and caveolin-1-independent endocytosis: Entry of simian virus 40 into cells devoid of caveolae. J Cell Biol 2005; 168: 477-488.
107. Lamaze C, Dujeancourt A, Baba T, Lo CG, Benmerah A, Dautry-Varsat A. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell 2001; 7: 661-671.
108. Kirkham M, Fujita A, Chadda R, Nixon SJ, Kurzchalia TV, Sharma DK, Pagano RE, Hancock JF, Mayor S, Parton RG. Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J Cell Biol 2005; 168: 465-476.
109. Sabharanjak S, Sharma P, Parton RG, Mayor S. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell 2002; 2: 411-423.
110. Acheson DWK, Calderwood SB, Boyko SA, Lincicome LL, Kane AV, Donohue-Rolfe A, Keusch GT. Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter system. Infect Immun 1993; 61: 1098-1104.
111. Calderwood SB, Auclair F, Dohanue-Rolfe A, Keusch GT, Mekalanos JJ. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc Natl Acad Sci USA 1987; 84: 4364-4368.
112. O’Brian AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT. Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992; 182: 65-94.
113. Sandvig K. The Shiga toxins: Properties and action on cells. In The Comprehensive Sourcebook of Bacterial Protein Toxins, 3rd edn., eds. J.E. Alouf and M.R. Popoff, pp. 310-322. Oxford, England:Academic Press, Elsevier Ltd., 2006.
114. Donohue-Rolfe A, Acheson A, Kane AV, Keusch GT. Purification of Shiga and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and the production of cross-reactive monoclonal antibodies. Infect Immun 1989; 57: 3888-3893.
115. Peter MG, Lingwood CA. Apparent cooperativity in multivalent verotoxin-globotriaosyl ceramide binding:Kinetic and saturation binding studies with [125I]verotoxin. Biochim Biophys Acta 2000; 1501: 116-124.
116. 3. Biochemistry 1998; 37: 1777-1788.
117. Iversen TG, Skretting G, van Deurs B, Sandvig K. Formation of clathrin-coated pits with long dynaminwrapped necks upon inducible expression of antisense clathrin. Proc Natl Acad Sci USA 2003; 100: 5175-5180.
118. Lauvrak SU, Togersen ML, Sandvig K. Efficient endosome-to-Golgi transport of Shiga toxin is dependent on dynamin and clathrin. J Cell Sci 2004; 117(Pt 11):2321-2331.
119. Saint-Pol A, Yélamos B, Amessou M, Mills IG, Dugast M, Tenza D, Schu P, Antony C, McMahon HT, Lamaze C, Johannes L. Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev Cell 2004; 6: 525-538.
120. Sandvig K, Olsnes S, Brown JE, Petersen OW, van Deurs B. Endocytosis from coated pits of Shiga toxin:A glycolipid-binding protein from Shigella dysenteriae 1. J Cell Biol 1989; 108: 1331-1343.
121. Nichols BJ, Kenworthy AK, Polishchuk RS, Lodge R, Roberts TH, Hirschberg K, Phair RD, Lippincott-Schwartz J. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 2001; 153: 529-541.
122. Kovbasnjuk O, Edidin M, Donowitz M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci 2001; 114(Pt 22):4025-4031.
123. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, Tenza, D, Aly MR, Fraisier V, Florent JC, Perrais D, Lamaze C, Raposo, G, Steinem C, Sens P, Bassereau P, Johannes L. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007; 450: 670-675.
124. Mallard F, Tenza D, Antony C, Salamero J, Goud B, Johannes L. Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of Shiga toxin-B fragment transport. J Cell Biol 1998; 143: 973-990.
125. Cabiaux V. pH-sensitive toxins: Interactions with membrane bilayers and application to drug delivery. Ad Drug Del Rev 2004; 56: 987-997.
126. Watson P, Spooner RA. Toxin entry and trafficking in mammalian cells. Ad Drug Del Rev 2006; 58: 1581-1596.
127. Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992; 358: 510-512.
128. Schapiro FB, Lingwood C, Furuya W, Grinstein S. pH-independent retrograde targeting of glycolipids to the Golgi complex. Am J Physiol 1998; 274: C319-C332.
129. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 1989; 264: 12115-12118.
130. Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol 2006; 7: 568-579.
131. Lombardi D, Soldati T, Riederer MA, Goda Y, Zerial M, Pfeffer SR. Rab9 functions in transport between late endosomes and trans Golgi network. EMBO J 1993; 12: 677-682.
132. Iversen TG, Skretting G, Llorente A, Nicoziani P, van Deurs B, Sandvig K. Endosome to Golgi transport of Ricin is independent of clathrin and of the Rab9-Rab11-GTPases. Mol Biol Cell 2001; 12: 2099-2107.
133. Lauvrak S, Llorente A, Iversen TG, Sandvig K. Selective regulation of the Rab9-independent transport of ricin to the Golgi apparatus by calcium. J Cell Sci 2002; 115: 3449-3456.
134. Sandvig K, Grimmer S, Lauvrak SU, Torgersen ML, Skretting G, van Deurs B, Iversen TG. Pathways followed by Ricin and Shiga toxin into cells. Histochem Cell Biol 2002; 117: 131-141.
135. Bujny MV, Popoff V, Johannes L, Cullen PJ. The retromer component sorting nexin-1 is required for efficient retrograde transport of Shiga toxin from early endosome to the trans Golgi network. J Cell Sci 2007; 120: 2010-2021.
136. Popoff V, Mardones GA, Tenza D, Rojas R, Lamaze C, Bonifacino JS, Raposo G, Johannes L. The retromer complex and clathrin define an early endosomal retrograde exit site. J Cell Sci 2007; 120: 2022-2031.
137. Amessou M, Fradagrada A, Falguieres T, Lord JM, Smith DC, Roberts LM, Lamaze C, Johannes L. Syntaxin 16 and syntaxin 5 are required for efficient retrograde transport of several exogenous and endogenous cargo proteins. J Cell Sci 2007; 120: 1457-1468.
138. Falguieres T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, Salamero J, Johannes L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell 2001; 12: 2453-2468.
139. Mallard F, Tang DBL, Galli T, Tenza D, Saint-Pol A, Yue X, Antony C, Hong WJ, Goud B, Johannes L. Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6 isoform. J Cell Biol 2002; 156: 653-664.
140. Monier S, Jollivet F, Janoueix-Lerosey I, Johannes L, Goud B. Characterization of novel Rab6-interacting proteins involved in endosome-to-TGN transport. Traffic 2002; 3: 289-297.
141. Wilcke M, Johannes L, Galli T, Mayau V, Goud B, Salamero J. Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-Golgi network. J Cell Biol 2000; 151: 1207-1220.
142. Tai G, Lu L, Wang TL, Tang BL, Goud B, Johannes L, Hong W. Participation of the syntaxin 5/Ykt6/GS28/GS15 SNARE complex in transport from early/recycling endosome to the trans-Golgi network. Mol Biol Cell 2004; 15: 4011-4022.
143. Altan-Bonnet N, Sougrat R, Lippincott-Schwartz J. Molecular basis for Golgi maintenance and biogenesis. Curr Op Cell Biol 2004; 16: 363-372.
144. Farquhar MG, Palade GE. The Golgi apparatus: 100 years of progress and controversy. Trends Cell Biol 1998; 8: 2-10.
145. Marsh BJ, Howell KE. The mammalian Golgi-complex debates. Nat Rev Mol Cell Biol 2002; 3: 789-795.
146. Johannes L, Tenza D, Antony C, Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga Toxin. J Biol Chem 1997; 272: 19554-19561.
147. Fujinaga Y, Wolf AA, Rodighiero C, Wheeler H, Tsai B, Allen L, Jobling MG, Rapoport T, Holmes RK, Lencer WI. Gangliosides that associate with lipid rafts mediate transport of Cholera and related toxins from the plasma membrane to the endoplasmic reticulum. Mol Biol Cell 2003; 14: 4783-4793.
148. Hessler JL, Kreitman RJ. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997; 36: 14577-14582.
149. Smith DC, Spooner RA, Watson PD, Murray JL, Hodge TW, Amessou M, Johannes L, Lord JM, Roberts LM. Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 2006; 7: 379-393.
150. Lippincott-Schwartz J, Yuan L, Bonifacino JS, Klausner RD. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from Golgi to ER. Cell 1989; 56: 801-813.
151. Sciaky N, Presley J, Smith C, Zaal KJ, Cole N, Moreira JE, Terasaki M, Siggia E, Lippincott-Schwartz J. Golgi tubule traffic and the effects of brefeldin A visualized in living cells. J Cell Biol 1997; 139: 1137-1155.
152. Girod A, Storrie B, Simpson JC, Johannes L, Goud B, Roberts LM, Lord JM, Nilsson T, Pepperkok R. Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat Cell Biol 1999; 1: 423-430.
153. Puri S, Linstedt, AD. Capacity of the Golgi apparatus for biogenesis from the endoplasmic reticulum. Mol Cell Biol 2003; 14: 5011-5018.
154. Ward TH, Polishchuk RS, Caplan S, Hirschberg K, Lippincott-Schwartz J. Maintenance of Golgi structure and function depends on the integrity of ER export. J Cell Biol 2001; 155: 557-570.
155. Miles S, McManus H, Forsten KE, Storrie, B. Evidence that the entire Golgi apparatus cycles in interphase HeLa cells: Sensitivity of Golgi matrix proteins to an ER exit block. J Cell Biol 2001; 155: 543-555.
156. Rhee SW, Starr T, Forsten-Williams K, Storrie B. The steady-state distribution of glycosyltransferases between the Golgi apparatus and the endoplasmic reticulum is approximately 90: 10. Traffic 2005; 6: 978-990.
157. Seemann J, Jokitalo E, Pypaert M, Warren G. Matrix proteins can generate the higher order architecture of the Golgi apparatus. Nature 2000; 407: 1022-1026.
158. Storrie B, White J, Rottger S, Stelzer EH, Suganuma T, Nilsson T. Recycling of Golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides explanation for nocodazole-induced Golgi scattering. J Cell Biol 1998; 143: 1505-1521.
159. Stroud WJ, Jiang S, Jack G, Storrie B. Persistence of Golgi matrix distribution exhibits the same dependence on Sar1p activity as a Golgi glycosyltransferase. Traffic 2003; 4: 631-641.
160. del Nery E, Miserey-Lenkei S, Falguieres T, Nizak C, Johannes L, Perez F, Goud B. Rab6A and Rab6A′ GTPases play non-overlapping roles in membrane trafficking. Traffic 2006; 7: 394-407.
161. White J, Johannes L, Mallard F, Girod A, Grill S, Reinsch S, Keller P, Tzschaschel B, Echard A, Goud B, Stelzer EHK. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. J Cell Biol 1999; 147: 743-759.
162. Young J, Stauber T, del Nery E, Vernos I, Pepperkok R, Nilsson T. Regulation of microtubule-dependent recycling at the trans-Golgi network by Rab6A and Rab6A′. Mol Cell Biol 2005; 16: 162-177.
163. Jiang S, Storrie B. Cisternal Rab proteins regulate Golgi apparatus redistribution in response to hypotonic stress. Mol Cell Biol 2005; 16: 2586-2596.
164. Valsdottir R, Hashimoto H, Ashman K, Koda T, Storrie B, Nilsson, T. Identification of rabaptin-5, rabex-5, and GM130 as putative effectors of Rab33b, a regulator of retrograde traffic between Golgi apparatus and ER. FEBS Lett 2001; 508: 201-209.
165. Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006; 25: 607-617.
166. Slominska-Wojewodzka M, Gregers TF, Walchli S, Sandvig S. EDEM is involved in retrotranslocation of Ricin from the endoplasmic reticulum to the cytosol. Mol Biol Cell 2006; 17: 1664-1675.
167. Schmitz A, Herrgen H, Winkeler A, Herzog V. Cholera toxin is exported from microsomes by the Sec61p complex. J Cell Biol 2000; 148: 1203-1212.
168. Yu M, Haslam DB. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect Immun 2005; 73: 2524-2532.
169. Ghosh RN, Mallet WG, Soe TT, McGraw TE, Maxfield FR. An endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking through the endocytic recycling compartment in CHO cells. J Cell Biol 1998; 142: 923-936.
170. Mallet WG, Maxfield FR. Chimeric forms of furin and TGN38 are transported from the plasma membrane to the trans-Golgi network via distinct endosomal pathways. J Cell Biol 1999; 146: 345-359.
171. Bachert C, Lee TH, Linstedt AD. Lumenal endosomal and Golgi-retrieval determinants involved in pH-sensitive targeting of and early Golgi protein. Mol Biol Cell 2001; 12: 3152-3160.
172. Natarajan R, Linstedt AD. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. Mol Biol Cell 2004; 15: 4798-4806.
173. Puri S, Bachert C, Fimmel CJ, Linstedt AD. Cycling of early Golgi proteins via the cell surface and endosomes upon luminal pH disruption. Traffic 2002; 3: 641-653.
174. Starr T, Forsten-Williams K, Storrie B. Both post-Golgi and intra-Golgi cycling affect the distribution of the Golgi phosphoprotein GPP130. Traffic 2007; 8: 1265-1279.
175. Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amiogorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165: 3301-3308.
176. LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, Singh D, Belch AR, Pilarski LM, Gariepy J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma, and absence from CD34+ hematopoietic stem cells: Implications of ex vivo tumor purging and autologous stem cell transplantation. Blood 1999; 94: 2901-2910.
177. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028.
178. Smith DC, Lord JM, Roberts LM, Tartour E, Johannes L. 1st class ticket to class I: Protein toxins as pathfinders for antigen presentation. Traffic 2002; 3: 697-704.
179. Kim Y, Kang K, Kim I, Lee J, Oh C, Ryoo J, Jeong E, Ahn K. Molecular mechanisms of MHC class I-antigen processing: Redox considerations. Antioxid Redox Signal 2009; 11: 908-936.
180. Haicheur N, Benchetrit F, Amessou M, Leclerc C, Falguieres T, Fayolle C, Bismuth E, Fridman WH, Johannes L, Tartour E. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int Immunol 2003; 15: 1161-1171.
181. Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman WH, Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol 1998; 28: 2726-2737.
182. Vingert B, Adotevi O, Patin D, Jung S, Shrikant P, Freyburger L, Eppolito C, Sapoznikov A, Amessou M, Quintin-Colonna F, Fridman WH, Johannes L, Tartour E. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36: 1124-1135.
183. Hakomori SI. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA 2002; 99: 10231-10233.
184. Arab S, Russel E, Chapman WB, Rosen B, Lingwood CA. Expression of the Verotoxin receptor glycolipid globotriaosylceramide, in ovarian hyperplasias. Oncol Res 1997; 9: 553-563.
185. Farkas-Himsley H, Hill R, Rosen B, Arab S, Lingwood CA. The bacterial colicin active against tumor cells in vitro and in vivo is Verotoxin 1. Proc Natl Sci USA 1995; 92: 6996-7000.
186. 3) expression in human tumor cells:Intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to Verotoxin. Acta Biochim Pol 1998; 45: 351-359.
187. Arab S, Murakami M, Dirks P, Boyd B, Habbard SL, Lingwood CA, Rutka JT. Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. J Neuro-Oncol 1998; 40: 137-150.
188. Salhia B, Rutka JT, Lingwood CA, Nutikka A, Van Furth WR. The treatment of malignant meningioma with Verotoxin. Neoplasia 2002; 4: 304-311.
189. Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, Kane A, Donowitz M. The glycosphingolipid globotriaosylceramide in metastatic transformation of colon cancer. Proc Natl Acad Sci USA 2005; 102: 19087-19092.
190. Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud M, Hakomori S. Changes in glycolipid expression in human testicular tumor. Int J Cancer 1990; 45: 1040-1044.
191. Ohyama C, Orikasa S, Satoh M, Saito S, Ohtani H, Fukushi Y. Globotriaosyl ceramide glycolipid in seminoma: Its clinicopathological importance in differentiation from testicular malignant lymphoma. J Urol 1992; 148: 72-75.
192. Hughes AK, Ergonul Z, Stricklett PK, Kohan DE. Molecular basis for high renal cell sensitivity to the cytotoxic effects of Shigatoxin-1: Upregulation of globotriaosylceramide expression. J Am Soc Nephrol 2002; 13: 2239-2245.
193. Lingwood CA. Glycolipid receptors for Verotoxin and Helicobacter pylori: Role in pathology. Biochim Biophys Acta 1999; 1455: 375-386.
194. Ohmi K, Kiyokawa N, Takeda T, Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 1998; 251: 137-141.
195. 3. J Infect Dis 1992; 166: 832-836.
196. Arbus GS, Grisaru S, Segal O, Dosch M, Pop M, Lala P, Nutikka A, Lingwood CA. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leuk Res 2000; 24: 857-864.
197. Butch AW, Nahm MH. Functional properties of human germinal center B cells. Cell Immunol 1992; 140: 331-344.
198. Bitzan M, Richardson S, Huang C, Boyd B, Petric M, Kamali MA. Evidence that Verotoxins (Shigalike toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun 1994; 62: 3337-3347.
199. Heath-Engel HM, Lingwood CA. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in xenograft tumor model: VT1 as a tumor neovascular marker. Angiogenesis 2003; 6: 129-141.
200. LaCasse EC, Saleh MT, Patterson B, Minden MD, Gariepy J. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 1996; 88: 1561-1567.
201. Tarragó-Trani MT, Jiang S, Harich KC, Storrie B. Shiga-like toxin subunit B (SLTB)-enhanced delivery of Chlorin e6 (Ce6) improves cell killing. Photochem Photobiol 2006; 82: 527-537.
202. 3 selectively potentiates its photodynamic activity. Bioconjug Chem 2008; 19: 532-538.
203. El Alaoui A, Schmidt F, Sarr M, Decaudin D, Florent JC, Johannes L. Synthesis and properties of a mitochondrial peripheral benzodiazepine receptor conjugate. Chem Med Chem 2008; 3: 1687-1695.
204. El Alaoui A, Schmidt F, Amessou M, Sarr M, Decaudin D, Florent JC, Johannes L. Shiga toxinmediated retrograde delivery to a topoisomerase I inhibitor prodrug. Angew Chem Int Ed Engl 2007; 46: 6469-6472.
205. Hicks S, Machamer CE. Golgi structure in stress sensing and apoptosis. Biochim Biophys Acta 2005; 1744: 406-414.
206. Storrie B, Tarragó-Trani MT, English S. B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging. United States Patent 6,631,283, 2003.
207. Jansen KP, Vignjevic D, Boisgard R, Falguieres T, Bousquet G, Decaudin D, Dolle F, Louvard D, Tavitian B, Robine S, Johannes L. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res 2006; 66: 7230-7236.
208. Viel T, Dransart E, Nemati F, Henry E, Theze B, Decaudin D, Lewandowski D, Boisgard R, Johannes L, Tavitian B. In vivo tumor targeting by the B-subunit of Shiga toxin. Mol Imaging 2008; 7: 239-247.